

Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets

Market Research Report | 2024-03-29 | 132 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

This research study analyzes the GI diagnostics and therapeutics market, offers revenue forecasts, assesses future trends and provides strategic recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028.

Report Includes:

- 43 data tables and 66 additional tables
- An overview of the global markets for gastrointestinal disease (GI) therapeutics and diagnostics.
- Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028.
- Discussion of the current and future market potential for GI therapeutics and diagnostics, along with an analysis of the competitive environment, regulatory scenario, and technological advances.
- Estimate of the market size and revenue forecast for the global market, and corresponding market share analysis by diagnostics type, end user and region.
- Facts and figures pertaining to the major market dynamics, opportunities and deterrents, emerging technologies, future prospects and the impacts of macroeconomic variables.
- A look at the GI therapeutics and diagnostic options currently available as well as potential products and classes of products that are likely to have an impact.
- Discussion of sustainability trends and ESG developments, with an emphasis on consumer attitudes, analysis of companies' ESG

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

scores, and the ESG practices followed by leading companies.

- Information pertaining to the recent developments and emerging technologies in the market.
- Review of current and potential treatment options and their impact on this market growth.
- A look at the industry structure, competitive aspects of each product segment, increasing investment in R&D, market development strategies, and company value share analysis.
- An analysis of the competitive landscape based on recent developments and segmental revenues.
- Profiles of the major global players, including Takeda Pharmaceutical Co. Ltd., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi, Bristol-Myers Squibb Co., and F. Hoffmann-La Roche Ltd.

Executive Summary

Summary:

The gastrointestinal (GI) tract extends from the mouth to the anus and includes structures such as the esophagus, stomach, small intestine, large intestine (colon), liver, gallbladder and pancreas. Gastrointestinal diseases can involve any part of this complex system. The most common gastrointestinal diseases include gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, peptic ulcer disease and gallstones. GI cancer is a group of cancers that affect the GI tract.

The global GI therapeutics and diagnostics market reached \$81.2 billion in 2022. This market is expected to reach \$122.5 billion through 2028, growing at a CAGR of 7.3% from 2023 through 2028.

GI prescriptions have remained one of the largest global therapeutic markets. The global prescription GI therapies market was estimated at \$58.7 billion in 2023. This market is expected to reach \$87.3 billion by the end of 2028. Rising incidence of GI disorders, such as irritable bowel syndrome (IBS), diarrhea, constipation, inflammatory bowel diseases and gastroesophageal reflux disease (GERD), as well as increasing therapeutic innovations, are key driving factors in the prescription GI therapies market. Growth is also influenced by an increase in the number of gastrointestinal cancers and increased drug prices due to newer, more effective treatments.

The global market for over-the-counter (OTC) GI therapies (e.g., laxatives, antacids, PPIs, H2 inhibitors, anti-diarrheals) was estimated at \$17.5 billion in 2023. This market is expected to reach \$22.1 billion, growing at a CAGR of 4.8% through 2028. The growth of the OTC therapies market is a multifaceted phenomenon driven by factors ranging from societal trends to regulatory changes and advancements in healthcare. Growing demand in emerging markets is a major driving force for the market.

The global market for GI endoscopy equipment was worth \$6.6 billion in 2022. It is estimated to reach \$9.8 billion by the end of 2028. The increasing prevalence of GI diseases, such as malignant and benign GI tumors, pancreaticobiliary stones, upper and lower GI bleeding, and pancreatitis, as well as the growing demand for minimally invasive devices for diagnosing and treating these conditions, are the key factors driving the market.

Table of Contents:

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Highlights of the Global Market for GI Therapeutics and Diagnostics
Chapter 2 Market Overview
Overview of the Gastrointestinal System

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Physiology of the GI System and the Role of Each Part in the GI Process

Chapter 3 Market Dynamics

Drivers

Increasing Prevalence of GI Cancer

Increasing Prevalence of GI Disorders

Growing Trend toward Screening and Preventive Care

Growing Adoption and Approval of Biological Drugs

High Unmet Need

Challenges

Loss of Exclusivity and Genericization

Regulatory and Safety Issues

Chapter 4 Emerging Technologies and Developments

Overview

Incorporation of AI and Other Digital Technologies

Single-Use Endoscopes

Focus on Biologics

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown

Global Market for Prescription GI Therapeutics, by Drug Type

Anti-inflammatories for Bowel Diseases

Gastrointestinal Cancer

Proton Pump Inhibitors

Anti-diarrheals

Others

Global Market for Prescription GI Drugs, by Type

Anti-inflammatories for Bowel Diseases

Gastrointestinal Cancer Therapeutics

Proton Pump Inhibitors

Anti-diarrheals

Others

Trends in the Market for Prescription GI Drugs

Global Market for Over-the-Counter GI Drugs, by Drug Type

Laxatives

Antacids

Proton Pump Inhibitors

Histamine-2 Blockers and Inhibitors

Anti-diarrheals

Global Market for Over-the-Counter GI Drugs, by Type

Laxatives

Antacids

Proton Pump Inhibitors

Histamine-2 Blockers

Anti-diarrheals

Opportunities in the Market of Over-the-Counter GI Medications

Global Market for Gastrointestinal Endoscopy Equipment

GI Endoscopes and Visualization Systems

GI Endotherapy Devices

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Market for GI Endoscopy Equipment, by Product
Technological Trends in the Market for GI Endoscopy
Global Market for GI Endoscopy Equipment, by Region
North America
Europe
Asia-Pacific
Rest of the World
Opportunities in the Market for GI Endoscopy Equipment
Global Market for GI Vaccines
Rotavirus Vaccine
Hepatitis
Hepatitis Vaccine
Global Market for GI Vaccines, by Disease Type
Global Market for Rotavirus Vaccines, by Region
Global Market for Hepatitis Vaccines by Region
Geographic Breakdown
Global Market for GI Therapeutics and Diagnostics, by Region
Market Revenue, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 6 Competitive Intelligence
Overview
Over-the-Counter GI Drugs
Prescription GI Drugs
GI Endoscopy Equipment
GI Vaccines
GI Disease Types
Disease Types
Inflammatory Bowel Diseases
GI Cancer
Gastroesophageal Reflux Disease
Chapter 7 Appendix
Methodology and Information Sources
Company Profiles
ABBVIE INC.
BAYER AG
BOSTON SCIENTIFIC CORP.
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC
HALEON GROUP OF CO.
JOHNSON & JOHNSON SERVICES INC.
OLYMPUS CORP.
PROCTER & GAMBLE
SANOFI

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets

Market Research Report | 2024-03-29 | 132 pages | BCC Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com